Strategies for management of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the "cidofovir as rescue treatment approaches.
Castagnola
E
E
Miano
M
M
Morreale
G
G
Cristina
E
E
Chierici
M
M
Lanino
E
E
D000956:Antigens, Viral / Q000097:blood*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D000077404:Cidofovir; D003587:Cytomegalovirus / Q000187:drug effects / Q000276:immunology / Q000302:isolation & purification / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000209:etiology; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D017245:Foscarnet / Q000008:administration & dosage / Q000627:therapeutic use; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010750:Phosphoproteins / Q000097:blood*; D012008:Recurrence; D016879:Salvage Therapy; D013997:Time Factors; D014184:Transplantation, Homologous / Q000009:adverse effects*; D014763:Viral Matrix Proteins / Q000097:blood*; D014766:Viremia / Q000188:drug therapy* / Q000209:etiology
D000956:Antigens, Viral; D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa; D017245:Foscarnet; D003596:Cytosine; D000077404:Cidofovir; D015774:Ganciclovir